

1 **Reference genome for the WHO reference strain for *Mycobacterium bovis* BCG Danish, the present**
2 **tuberculosis vaccine**

3 Katlyn Borgers^{a,b*}, Jheng-Yang Ou^{c,d*}, Po-Xing Zheng^{c,d}, Petra Tiels^{a,b}, Annelies Van Hecke^{a,b}, Evelyn Plets^{a,b}, Gitte
4 Michielsen^{a,b}, Nele Festjens^{a,b}, Nico Callewaert^{a,b#}, Yao-Cheng Lin^{c,d#}

5 ^aVIB-UGhent Center for Medical Biotechnology; Technologiepark-Zwijnaarde 71, 9052 Ghent, Belgium

6 ^bDepartment of Biochemistry and Microbiology, Ghent University; Technologiepark-Zwijnaarde 71, 9052 Ghent,
7 Belgium

8 ^cBiotechnology Center in Southern Taiwan, Academia Sinica, Tainan 74145, Taiwan

9 ^dAgricultural Biotechnology Research Center, Academia Sinica, Tainan 74145, Taiwan

10 * Equal contributions

11 # Joint corresponding authors

12 **ABSTRACT**

13 *Mycobacterium bovis* bacillus Calmette-Guérin (*M. bovis* BCG) is the only vaccine available against
14 tuberculosis (TB). This study reports on an integrated genome analysis workflow for BCG, resulting in the
15 completely assembled genome sequence of BCG Danish 1331 (07/270), one of the WHO reference strains
16 for BCG vaccines. We demonstrate how this analysis workflow enables the resolution of genome
17 duplications and of the genome of engineered derivatives of this vaccine strain.

18 **MAIN TEXT**

19 The BCG live attenuated TB vaccine is one of the oldest and most widely used vaccines in human medicine.
20 Each year, BCG vaccines are administered to over 100 million newborns (i.e. 75% of all newborns on the
21 planet). The original BCG strain was developed in 1921 at the Pasteur Institute, through attenuation of the
22 bovine TB pathogen *M. bovis*, by 231 serial passages on potato slices soaked in glycerol-ox bile over a time-
23 span of 13 years¹. This BCG Pasteur strain was subsequently distributed to laboratories around the world
24 and different laboratories maintained their own daughter strains by passaging. Over the years, different
25 substrains arose with different protective efficacy^{2,3}. The establishment of a frozen seed-lot system in 1956
26 and the WHO recommendation of 1966 that vaccines should not be prepared from cultures that had
27 undergone >12 passages starting from a defined freeze-dried seed lot, halted the accumulation of
28 additional genetic changes¹. In an effort to further standardize the vaccine production and to prevent
29 severe adverse reactions related to BCG vaccination, three substrains, i.e. Danish 1331, Tokyo 172-1 and
30 Russian BCG-1 were established as the WHO reference strains in 2009 and 2010⁴. Of these, the BCG Danish
31 1331 strain is the most frequently used one, and it also serves as a basis of most current “next-generation”
32 engineering efforts to improve the BCG vaccine or to use it as a “carrier” for antigens of other pathogens^{5,6}.
33 Complete genome elucidation of BCG strains is challenging by the occurrence of large genome segment

34 duplications and a high GC content. Therefore, no fully assembled reference genome is yet available for
35 BCG Danish, only incomplete ones^{7,8}, which hinders further standardization efforts.

36 By combining second (Illumina) and third (PacBio) generation sequencing technologies and an integrated
37 bioinformatics workflow we have for the first time fully assembled the BCG Danish 1331 (07/270) strain
38 genome sequence. Ambiguous regions were locally reassembled and/or experimentally verified. The single
39 circular chromosome is 4,411,814 bp in length and encodes 4,084 genes, including 4,004 genes encoding
40 for proteins, 5 genes for rRNA, 45 genes for tRNA and 30 pseudogenes (**Fig. 1a**). Compared to the reference
41 genome sequence of BCG Pasteur 1173P2, 42 SNPs were identified and a selected subset was validated
42 (**Suppl. Table 1 and 5**). Genetic features determinative for BCG Danish, as described by Abdallah *et al.*⁸,
43 were identified, including the region of difference (RD) Denmark/Glaxo and the DU2 type III, that was
44 completely resolved in the assembly (**Fig. 1a-b**). Additionally, a 1 bp deletion in Mb3865 and a 465 bp
45 insertion in PE_PGRS54 compared to BCG Pasteur were found. The organization of 2 repeats (A and B) in
46 PE_PGRS54 has been reported to differ between the BCG strains⁹. We report a A-A-B-B-B-B organization for
47 BCG Danish in contrast to BCG Tokyo (A-A-B-B-B) and BCG Pasteur (A-B-B-B-B). Previously, two separate
48 genetic populations for BCG Danish 1331 have been described, which differ in the SenX3-RegX3 region
49 (having 2 or 3 repeats of 77 bp)¹⁰. For BCG Danish 1331 07/270 we document only 3 repeats of 77 bp
50 (**Suppl. Fig. 2**). Two features described by Abdallah *et al.*⁸ to be determinative for BCG Danish were not
51 identified, namely the rearrangement of the *fadD26-pssA* gene region and a 894 bp del in Mb0096c-
52 Mb0098c. In addition, a 399 bp instead of 118 bp insertion was detected in *leuA*, giving 12 direct repeats of
53 57 bp, as in the Pasteur strain (previously denoted as S-RD13¹¹). These differences are likely due to inherent
54 repeat structures in these regions, which cannot be resolved by short sequencing reads (as used in Abdallah
55 *et al.*⁸), but require long sequencing reads, as generated by PacBio SMRT sequencing in this study.

56 Two large tandem chromosomal duplications characterize the BCG strains; the DU2 and DU1 (**Fig. 2, Suppl.**
57 **Table 6**). While four different forms of the DU2 exist, the DU1 is supposed to be exclusively present in BCG
58 Pasteur¹¹⁻¹³; it spans the chromosomal origin of replication or *oriC* (*dnaA-dnaN* region) and encodes key
59 components of the replication initiation and cell division machinery. Surprisingly, we detected a DU1-like
60 duplication of 14,577 bp in BCG Danish (**Fig. 1**). To adapt an unambiguous terminology, we considered all
61 duplications spanning the *oriC* as DU1, while specifying the strain in which the duplication was found.
62 Investigation of other publicly available data for BCG Danish did not show presence of a DU1 (**Fig. 1c, Suppl.**
63 **Fig. 1**), indicating that only the Danish 1331 substrain deposited as the WHO reference at the National
64 Institute for Biological Standards and Control (NIBSC) contains this duplication. Additional inconsistencies in
65 DU1 presence/absence were detected by reanalyzing publicly available data (**Fig. 1c, Suppl. Fig. 1**). In
66 contrast to the literature, we detected BCG Pasteur substrains with a DU1 (data ref¹³) and without a DU1
67 (data ref^{8,14}). Similarly, experimental analysis of our in-house Pasteur strains (1721, 1173 ATCC 35734)
68 showed absence of a DU1 (**Fig. 1d**). Additionally, a DU1-China was detected (data ref^{7,13}), but not in the

69 data of Abdallah *et al.* 2015⁸, which could be explained by the use of two different substrains of BCG that
70 are both named BCG China⁸. DU1-Birkhaug was consistently detected in all reported sequencing data of
71 that BCG strain. The genealogy of BCG strains is thus further complicated by the genomic instability of the
72 *oriC* during *in vitro* cultivation (**Fig. 2, Suppl. Table 6**). A DU1-like duplication has also been identified in a
73 ‘non-vaccine’ strain; in a clinical isolate (3281), identified as BCG, a 7-kb region that covered six genes and
74 crossed the *oriC* was repeated three times¹⁵, further indicating that this region is prone to duplication.
75 Together, these data underline the importance of the genomic characterization of BCG strains used as
76 vaccines, including their dynamic duplications.

77 To demonstrate how this genome analysis methodology contributes to full characterization of improved
78 BCG-derived engineered vaccines, we applied it to a knock-out mutant (KO) for the *sapM* secreted acid
79 phosphatase, located in the analytically challenging long duplication region DU2¹¹. Our BCG genome
80 analysis workflow unequivocally demonstrated that the KO engineering had inadvertently out-recombined
81 one of the copies of this DU2 and had given rise to a single SNP (**Suppl. Fig. 4, Suppl. Table 1 and 5**). Such
82 unexpected genomic alterations are likely common in engineered live attenuated TB vaccines, but have so
83 far gone unnoticed due to lack of a complete reference genome and or suitable genome analysis
84 methodology.

85 The implementation of both short (Illumina) and long (PacBio) sequencing reads in one genome analysis
86 methodology allows the straightforward generation of completely assembled genomes of BCG strains.
87 These include the decomposition of the analytically challenging long duplications regions DU1 and DU2,
88 wherefore one formerly needed additional experimental methods (e.g. gap closure via PCR¹⁵).

89 The availability of the complete reference genome for BCG Danish 1331 as well as the associated genome
90 analysis workflow, now permits full genomic characterization of (engineered) TB vaccine strains, which
91 should contribute to more consistent manufacturing of this highly cost-effective vaccine that protects the
92 world’s newborns from disseminated TB.

93 **FIGURES**





Figure 1. Organization of the BCG Danish 1331 (07/270) genome, focusing on the DU1 and DU2. a) Circular representation of the BCG Danish chromosome. The scale is shown in megabases on the outer black circle. Moving inward, the next two circles show forward (dark blue) and reverse (yellow) strand CDS. The next circle shows tRNA (black) and rRNA (orange) genes, followed by 42 SNPs (red) detected between BCG Danish and Pasteur. The subsequent circle shows DU2-III (dark blue), DU1-Danish (purple) and RD (light blue, names of RD in black) that are typical for BCG Danish. The two inner circles represent G+C content and GC skew. **b)** Organization of the two tandem duplications in BCG Danish and confirmation by PCR. The DU2 is made up by two repeats (R1 and R2), as well as the DU1-Danish (R3 and R4). Used primer pairs (1-8) to validate their organization are indicated. **c)** Visual representation of the *oriC* with position and size of DU1-China, -Danish, -Pasteur and -Birkhaug. The table indicates which substrains have the DU1. **d)** Copy-number analysis of genes (indicated in grey in **subfigure c**) in and surrounding the DU1 region for Pasteur 1173 (ATCC 35734), Pasteur 1721 and Danish 1331 (07/270). The represented data are averages (\pm SD) of four technical replicates.



144 **Figure 2. Refined genealogy of BCG vaccine strains.** The year when the strain was obtained per geographical location
 145 is indicated where possible (indigo). The scheme shows regions of difference (RD), insertions (Ins), deletions ('Δ'),
 146 indels, tandem duplications (DU), which differentiate the different BCG strains (**Suppl. Table 6**). The blue dashed
 147 squares indicate the different DU2-forms, which classify the BCG strains into four major lineages. When the DU1 is not
 148 found in all substrains of a certain strain, this is indicated on the scheme. According to the literature, two different
 149 substrains of BCG are named BCG China or Beijing⁸. Therefore, the scheme contains two 'BCG China' strains: BCG
 150 China⁸ and BCG China*^{7,13}. Adapted from refs ^{8,11,13,16,17}. Concerning ref ⁸, only the RD and deleted genes that could be
 151 verified on the assembled genomes are included.

152 **METHODS**

153 **Mycobacterial strains, gDNA and reference genomes**

154 The strains used include the *M. bovis* BCG Danish 1331 sub-strain (1st WHO Reference Reagent, 07/270,
155 National Institute for Biological Standards and Control (NIBSC), Hertfordshire), the BCG Pasteur 1173 strain
156 (ATCC®35734TM, ATCC, Manassas), the streptomycin-resistant BCG Pasteur 1721 strain¹⁸ (*RpsL*: K43R; a gift
157 of Dr. P. Sander, Institute for Medical Microbiology, Zürich). From the Danish 1331 strain a $\Delta sapM$ (KO)
158 strain was constructed (detailed procedure of the strain construction can be found in **Suppl. Methods**).
159 Strains were grown in Middlebrook 7H9 broth (Difco) supplemented with 0.05% Tween-80 and
160 Middlebrook OADC (Becton Dickinson). Preparation of gDNA from mycobacterial strains was performed as
161 previously described¹⁹. As reference genomes, *M. tb* H37Rv (NC_000962.3), *M. bovis* AF2122_97
162 (NC_002945.4) and BCG Pasteur 1173P2 (NC_008769.1) were used.

163

164 **Whole genome sequencing of BCG Danish 1331 WT and *sapM* KO strain**

165 For PacBio SMRT sequencing, the gDNA was sheared (large hydropore, Megaruptor device, Diagenode),
166 used for a PacBio SMRT library prep (SMRTbell Temp Prep Kit 1.0, Pacific Biosciences) and sequenced on an
167 PacBio RSII instrument (DNA/Polymerase Binding Kit P6 v2, Pacific Biosciences). 1 SMRT-cell was run for the
168 KO sample (229x coverage) and 2 SMRT-cells were run for the WT sample (140x and 95x coverage). For
169 Illumina sequencing, libraries were prepared with Nextera DNA Library Preparation kit and sequenced on
170 an Illumina MiSeq instrument (MiSeq Reagent Kit v2 Nano, PE250, 500 Mb), with an average of 55-56x
171 coverage per genome.

172

173 **Genome assembly and analysis (Suppl. Fig. 3)**

174 Illumina reads were quality-filtered and trimmed (Trimmomatic-0.36) after which the paired-end reads
175 were merged with overlapping sequence (BBmerged v36.69). PacBio reads were corrected using the
176 trimmed Illumina reads (Lordec v0.6). The unmerged and merged Illumina reads were assembled (SPAdes
177 v3.9.0) into a draft assembly, which was scaffolded using the corrected PacBio reads (SSPACE-LongRead
178 v3.0). Gaps in the scaffold were closed (GapFiller v1.10) and finally the assembly was improved using the
179 trimmed Illumina reads (Pilon v1.20).

180 The exact sequence of the DU1 region was based on a second round of local *de novo* assembly (SPAdes
181 v3.9.0) using soft-clipped Illumina reads surrounding the draft DU1 region where the Illumina read
182 coverage is more than two times higher than the background coverage. The DU2 repeat was resolved by
183 comparing SPAdes assembly with the assembly from HINGE (v201705), where the R1 and R2 regions have
184 been separated. The junction sequences of DU1 and DU2 were further confirmed by aligning uniquely
185 mapped PacBio reads, or by PCR and Sanger sequencing.

186 Annotation was done by combining an automatic gene prediction program with heuristic models
187 (GeneMark.hmm) and the existing Pasteur and *M. tb* reference gene models (GMAP and TBLASTN) along

188 with UniProt database (BLASTP). Non-coding RNA were predicted (tRNAScan-SE and Infernal). The assigned
189 annotations were manually checked (Artemis and CLC Main Workbench 8, e.g. correct start codon), by
190 comparative analysis with the 3 reference genomes for *M. tb*, *M. bovis* and Pasteur, as listed above.
191 Inconsistencies in the annotation and/or assembly were analyzed in detail and/or verified by PCR and
192 Sanger Sequencing.

193 A probabilistic variant analysis was performed by mapping the BBmerged Illumina reads to the Pasteur
194 reference genome (BWA-MEM) and calling variants by GATK UnifiedGenotyper (Count ≥ 10 & Variant
195 Probability > 0.9), whereafter variant annotations and functional effect prediction were carried out with
196 SnpEff and SnpSift. The orthologous relationships between *M. tb*, BCG Pasteur and BCG Danish WT and
197 *sapM* KO were investigated: the proteins of strains (BCG Danish WT and *sapM* KO, BCG Pasteur 1173P2,
198 H37Rv) were searched using all-against-all with BLASTP, after which the result was analyzed by TribeMCL
199 and i-ADHoRe 3.0 based on the genome synteny information (**Suppl. Table 7**).

200 To validate the detection of the DU1, the DU1 duplication region was reanalyzed with published genome
201 data from ref ^{7,8,13,14}. Illumina short sequencing reads or probes on tiling array were mapped to the *M. tb*
202 reference strain (BWA-MEM) after which the DU1 duplications were detected (cn.mops).

203 In **Suppl. Fig. 3** a graphical overview of the performed genome analysis pipeline is given and in
204 **Supplementary Methods** a citation list was incorporated for the used bioinformatics tools and databases.

205

206 **PCR analysis, gel electrophoresis and Sanger Sequencing**

207 PCR (GoTaq[®]Green, Promega) was performed on gDNA using primers listed in **Suppl. Table 2**. PCR products
208 were run on a 1.2% agarose gel, stained with Midori Green and visualized under ultraviolet light. To confirm
209 the SNP variants, regions of interest were amplified (Phusion High-Fidelity DNA Polymerase, NEB) from
210 gDNA with primers listed in **Suppl. Table 3**. The resulting PCR products were purified (AMPure XP beads)
211 and Sanger sequenced with (a) nested primer(s) (**Suppl. Table 3**).

212

213 **Copy number profiling via qPCR**

214 Real-time quantitative PCR was done on a LightCycler 480 (Roche Diagnostics) using the SensiFast SYBR-
215 NoRox kit (Bioline) in quadruplicate for each gDNA sample using primers listed in **Suppl. Table 4**.
216 Determination of the average relative quantities was performed using the qbasePLUS software (Biogazelle).
217 All results were normalized using the reference genes 16S rRNA, *nuoG* and *mptpB*.

218

219 **ACKNOWLEDGEMENTS**

220 We thank Dr. Peter Sander (Institute for Medical Microbiology, Faculty of Medicine, University of Zurich) for
221 providing us with the BCG strain 1721. We thank the DRESDEN-concept Genome Center (MPI-CBG,
222 Dresden) for the PacBio library prep and sequencing services. We thank Insight Genomics Inc. (Tainan,
223 Taiwan) for the Illumina library prep and sequencing services. We thank the VIB Genetics Service Facility,
224 (<http://www.vibgeneticservicefacility.be>, Antwerp) for the Sanger sequencing services. Research was
225 funded through a PhD fellowship to K.B. from the Flanders Innovation & Entrepreneurship agency (VLAIO),
226 an ERC Consolidator grant 'GlycoTarget' to N.C., VIB and UGhent institutional funding to N.C., and
227 Academia Sinica institutional funding to Y.-C.L.

228

229 The authors declare no competing interests.

230

231 **AUTHOR CONTRIBUTIONS**

232 K.B. designed and performed the experiments, analyzed the data and co-wrote the manuscript. J.-Y.O
233 performed the bioinformatics analysis. P.-X.Z. assisted in the data analysis. G.M. assisted in performing the
234 experiments. E.P. performed the RT-qPCR analysis. P.T. and A.H. constructed pGoal17SapM700 and
235 transformed BCG Danish 1331 with this plasmid. N.F. assisted in experimental interpretation and carefully
236 revised the manuscript. N.C. initiated the project, assisted in experimental design and interpretation and
237 co-wrote the manuscript. Y.-C.L. performed the bioinformatics analysis, assisted in experimental design and
238 interpretation and co-wrote the manuscript.

239

240 **DATA AVAILABILITY STATEMENT**

241 The raw sequencing data (raw Illumina and PacBio reads, and PacBio base modification files) generated by
242 this study for the BCG Danish 1331 WT and *sapM* KO strain, the complete genome assemblies and
243 annotation have been deposited in GenBank with the primary accession codes BioProject PRJNA494982.
244 The data (other than the next-generation sequencing data) that support the findings of this study are
245 available on request from the corresponding author N.C..

246

247 **REFERENCES**

- 248 1. Lugosi, L. Theoretical and methodological aspects of BCG vaccine from the discovery of Calmette and
249 Guérin to molecular biology. A review. *Tuber. Lung Dis. Off. J. Int. Union Tuberc. Lung Dis.* **73**, 252–261
250 (1992).
- 251 2. Ritz, N., Hanekom, W. A., Robins-Browne, R., Britton, W. J. & Curtis, N. Influence of BCG vaccine strain
252 on the immune response and protection against tuberculosis. *FEMS Microbiol. Rev.* **32**, 821–841
253 (2008).
- 254 3. Zhang, L. *et al.* Variable Virulence and Efficacy of BCG Vaccine Strains in Mice and Correlation With
255 Genome Polymorphisms. *Mol. Ther.* **24**, 398–405 (2016).
- 256 4. Ho, M. M., Markey, K., Rigsby, P., Hockley, J. & Corbel, M. J. Report of an International collaborative
257 study to establish the first WHO reference reagents for BCG vaccines of three different sub-strains.
258 *Vaccine* **29**, 512–518 (2011).
- 259 5. Zheng, Y. *et al.* Applications of bacillus Calmette–Guerin and recombinant bacillus Calmette–Guerin in
260 vaccine development and tumor immunotherapy. *Expert Rev. Vaccines* **14**, 1255–1275 (2015).
- 261 6. Nieuwenhuizen, N. E. & Kaufmann, S. H. E. Next-Generation Vaccines Based on Bacille Calmette–
262 Guérin. *Front. Immunol.* **9**, (2018).
- 263 7. Pan, Y. *et al.* Whole-Genome Sequences of Four Mycobacterium bovis BCG Vaccine Strains. *J. Bacteriol.*
264 **193**, 3152–3153 (2011).
- 265 8. Abdallah, A. M. *et al.* Genomic expression catalogue of a global collection of BCG vaccine strains show
266 evidence for highly diverged metabolic and cell-wall adaptations. *Sci. Rep.* **5**, 15443 (2015).
- 267 9. Seki, M. *et al.* Whole genome sequence analysis of Mycobacterium bovis bacillus Calmette–Guérin
268 (BCG) Tokyo 172: A comparative study of BCG vaccine substrains. *Vaccine* **27**, 1710–1716 (2009).
- 269 10. Bedwell, J., Kairo, S. K., Behr, M. A. & Bygraves, J. A. Identification of substrains of BCG vaccine using
270 multiplex PCR. *Vaccine* **19**, 2146–2151 (2001).
- 271 11. Brosch, R. *et al.* Genome plasticity of BCG and impact on vaccine efficacy. *Proc. Natl. Acad. Sci.* **104**,
272 5596–5601 (2007).
- 273 12. Brosch, R. *et al.* Comparative Genomics Uncovers Large Tandem Chromosomal Duplications in
274 Mycobacterium Bovis BCG Pasteur. *Yeast Chichester Engl.* **17**, 111–123 (2000).
- 275 13. Leung, A. S. *et al.* Novel genome polymorphisms in BCG vaccine strains and impact on efficacy. *BMC*
276 *Genomics* **9**, 413 (2008).
- 277 14. Festjens, N. *et al.* SapM mutation to improve the BCG vaccine: genomic, transcriptomic and preclinical
278 safety characterization. *bioRxiv* 486993 (2018). doi:10.1101/486993
- 279 15. Li, X. *et al.* Genomic Analysis of a Mycobacterium Bovis Bacillus Calmette-Guérin Strain Isolated from
280 an Adult Patient with Pulmonary Tuberculosis. *PLOS ONE* **10**, e0122403 (2015).
- 281 16. Bottai, D. & Brosch, R. The BCG Strain Pool: Diversity Matters. *Mol. Ther.* **24**, 201–203 (2016).
- 282 17. Abdallah, A. M. & Behr, M. A. Evolution and Strain Variation in BCG. in *Strain Variation in the*
283 *Mycobacterium tuberculosis Complex: Its Role in Biology, Epidemiology and Control* 155–169 (Springer,
284 Cham, 2017). doi:10.1007/978-3-319-64371-7_8
- 285 18. Master, S. S. *et al.* Mycobacterium tuberculosis Prevents Inflammasome Activation. *Cell Host Microbe*
286 **3**, 224–232 (2008).
- 287 19. Vandewalle, K. *et al.* Characterization of genome-wide ordered sequence-tagged Mycobacterium
288 mutant libraries by Cartesian Pooling-Coordinate Sequencing. *Nat. Commun.* **6**, 7106 (2015).
- 289 20. Parish, T. & Stoker, N. G. Use of a flexible cassette method to generate a double unmarked
290 Mycobacterium tuberculosis tlyA plcABC mutant by gene replacement. *Microbiol. Read. Engl.* **146 (Pt**
291 **8)**, 1969–1975 (2000).
- 292

293 **SUPPLEMENTARY DATA**

294 Supplementary Methods

295

296 Supplementary Figure 1. DU1 duplication detection in BCG strains

297 Supplementary Figure 2. Analysis of the SenX3-RegX3 region in BCG strains

298 Supplementary Figure 3. Genome analysis pipeline

299 Supplementary Figure 4. Generation and characterization of BCG Danish 1331 *sapM* KO

300

301 Supplementary Table 1. Summary table of SNPs detected in *M. bovis* Danish 1331 WT and *sapM* KO
302 compared to the Pasteur reference 1173P2 (NC_008769.1)

303 Supplementary Table 2. PCR primer pairs for confirmation of the genome assembly

304 Supplementary Table 3. PCR primer pairs for confirmation of the SNP variants

305 Supplementary Table 4. qPCR primer pairs for copy number profiling

306 Supplementary Table 5*. SNPs detected in *M. bovis* Danish 1331 WT and *sapM* KO compared to the Pasteur
307 reference 1173P2 (NC_008769.1)

308 Supplementary Table 6*. Distribution of regions of difference, deletions and tandem duplications (DU1 and
309 DU2) in the different BCG strains compared to *M. bovis*

310 Supplementary Table 7*. Ortholog of mycobacterial genes between *M. tb* H37Rv, *M. bovis* BCG Pasteur, *M.*
311 *bovis* BCG Danish WT and *sapM* KO.

312

313 * Supplementary Table 5 to 7 are provided as Excel files.

314 SUPPLEMENTARY METHODS

315 Generation of *M. bovis* BCG Danish 1331 *sapM* KO

316 A *sapM* KO construct was made with the p2NIL and pGOAL17 vectors²⁰. Hereto, a 5' and 3' sequence part of *sapM* of
317 700 bp was amplified by PCR from gDNA of *M. bovis* BCG (5' Fw primer: ctgcagggtggtgggttctctcgcg, 5' Rv primer:
318 attacctgttatccctacggcgaacgcctggccatc, 3' Fw primer: tagggataacagggttaattagccgcctcgtctattctgtg, 3' Rv primer
319 aagcttctcgtcgcggactggcgcg). In the 5' Rv primer a stop codon was inserted to ensure that a truncated *sapM* is formed.
320 The 5' and 3' part were fused by performing a PCR with the 5' Fw primer and 3' Rv primer. The resulting fragment was
321 cut with PstI and HindIII and ligated in the p2NIL vector cut with the same restriction enzymes. This p2NILSapM700
322 vector was then cloned into the PacI site of the pGOAL17 vector to create the pGOAL17SapM700 vector (**Suppl. Fig.**
323 **4a**).

324 For the electroporation, *M. bovis* BCG Danish 1331 was grown to mid-log phase (OD₆₀₀ 0.4-0.8) in 7H9-ADS-Tw
325 medium (7H9 + 50 g/L bovine serum albumin fraction V, 20 g/L dextrose, 8.5 g/L NaCl, 0.05% Tween-80). 1.5% glycine
326 was added into the culture the day before electroporation. On the day of electroporation, cells were harvested in 50
327 ml conical tubes at room temperature at 3700 rpm for 10 minutes. The cells were washed twice with 50 ml 0.05%
328 Tween-80 (pre-warmed at 37°C), after which the cells were resuspended in 1 ml of 0.05% Tween-80. The UV-
329 irradiated plasmid (100 mJ/cm², to stimulate homologous recombination) was added to 200 µl of bacterial cells after
330 which the electroporation was performed (GenePulser apparatus (Bio-Rad) set at 2500 mV, resistance 800 ohms,
331 capacitance 25 µF). The cells were diluted with 1 ml of 7H9-ADS-Tw (pre-warmed at 37°C) after which 4 ml medium
332 was added and the culture was placed overnight at 37°C. The culture was plated out on 7H10 with 50 µg/ml
333 kanamycin and 50 µg/ml X-gal. The one blue colony (presence of *lacZ*) that was formed, was tested with colony PCR
334 for the integration of the plasmid and grown in liquid 7H9 medium without kanamycin to stimulate a second
335 homologous recombination, resulting in knocking out the *sapM* gene. To select for the clones that have lost the
336 plasmid, the culture was plated on 7H10 + 2% sucrose + 50 µg/ml X-gal (presence of *sacB* which inhibits growth on
337 sucrose medium). Several white colonies were tested for the absence of *sapM*, by means of PCR. One clone was
338 selected for further work, which showed absence of SapM expression and thus lost both *sapM* loci (**Suppl. Fig. 4b**).
339 This was confirmed by PCR, Southern Blot, copy number analysis via qPCR, qPCR-RT analysis, SapM ELISA and
340 phosphatase assay (**Suppl. Fig. 4c-i**). The SapM ELISA and phosphatase assay were performed as described in ref¹⁴.

341

342 Southern blot

343 To verify if deletion of the *sapM* gene had occurred, genomic DNA of the strains was digested with PvuII. The digested
344 samples were blotted to an Amersham Hybond-N+ membrane (GE Healthcare) by the neutral denaturing procedure
345 (see manufacturer's instructions). We hybridized the membranes with a DIG-labelled *sapM* probe, created by PCR
346 amplifying a region overlapping with the 5' end of *sapM* (primers GGCTGGTGGGTTTGCTCGTCG and
347 TGCCAGACCACTTGTGGGACA) using a DIG-labeled synthetic dNTP mix (Roche Life Sciences). The membrane was
348 incubated with an anti-DIG-AP antibody (1:10,000) (Roche Life Sciences), washed twice with washing buffer (0.1 M of
349 maleic acid, 0.15 M of NaCl and 0.3% Tween-20, pH 7.5) and developed with the Amersham CDP-Star substrate in
350 detection buffer (1:100 dilution) (GE Healthcare). The luminescent signal was measured by exposure to an X-ray film.
351 The expected Southern Blot band for the WT was 2206 bp and 1598 bp for the *sapM* KO (**Suppl. Fig. 4c**).

352

353 **RT-qPCR analysis**

354 *M. bovis* BCG cultures (grown in standard 7H9 medium until an OD₆₀₀ of 0.8 – 1.0) were centrifuged and the pellets
355 were washed once with sterile water containing 0.5% Tween-80. The pellet was then resuspended in 500 µl of RLT
356 buffer (RNeasy Mini Kit, Qiagen; supplemented with β-ME). The cells were disrupted with glass beads in a Retsch
357 MM2000 bead beater at 4°C in screw-cap tubes (pre-baked at 150°C). After centrifugation (2 min, 13,000 rpm, 4°C),
358 the supernatant was transferred to a fresh eppendorf tube. To recover the lysate trapped in between the beads, 800
359 µl of chloroform was added to the beads and centrifuged, after which the upper phase was transferred to the same
360 eppendorf tube as before. Then, 1 volume of Acid Phenol/Chloroform (Ambion) was added, incubated for 2 minutes
361 and centrifuged (5 min, 13,000 rpm, 4°C). The upper aqueous phase was transferred to a fresh eppendorf tube and
362 this last step was repeated once. An equal volume of 70% ethanol was added and the sample was transferred to an
363 RNeasy spin column (RNeasy Mini Kit, Qiagen). The kit manufacturer's instructions were followed to purify the RNA.
364 After elution in RNase-free water (30 µl), an extra DNase digestion was performed with DNaseI (10 U of enzyme, 50 µl
365 reaction volume). Then an extra clean-up step was performed with the RNeasy Mini Kit (Qiagen). Finally, the RNA
366 concentration was determined on a Nanodrop instrument.

367 cDNA was prepared from 1 µg of DNase-treated RNA using the iScript Synthesis Kit (BioRad) and a control reaction
368 lacking reverse transcriptase was included for each sample. The RT-PCR program was as follows: 10 min at 25°C, 30
369 min at 42°C, 5 min at 85°C.

370 Real time quantitative PCR was done on a LightCycler 480 (Roche Diagnostics) using the SensiFast SYBR-NoRox kit
371 (BioLine), in triplicate for each cDNA sample. All gene expression values were normalized using the geometric mean of
372 the *gap* and *pgk* rRNA. Determination of amplification efficiencies and conversion of raw Cq values to normalized
373 relative quantities (NRQ) was performed using the qbasePLUS software. Statistical analysis of the NRQs was done with
374 the Prism6.04 software package using an unpaired t-test, we corrected for multiple comparisons using the Holm-Sidak
375 method (alpha = 0.05).

376 Primers used in the experiment: *gap* (TGGGAGTTAACGACGACAAG and ACTCATCGTCGAGCACTTTG), *pgk*
377 (GAAACCAGCAAGAACGATGA and AACAGGGTTGCGATGTCATA), *upp* (CGGGTCGCGGCTAAC and
378 GGGCAGCGAGTCCAGATA), *sapM* (TGCGGCCCGAACTTACAACGAGA and CAAGCGGATGGGTACGAGGTACGC) and
379 BCG_3376 (AAGTTCTTCAACGGCAATCC and GTGCTGATGATCTCGTCGAT).

380

381 **Citation list for the used bioinformatics tools and database**

382 *Artemis* – Carver, T., Harris, S. R., Berriman, M., Parkhill, J. & McQuillan, J. A. Artemis: an integrated platform for visualization and
383 analysis of high-throughput sequence-based experimental data. *Bioinformatics* 28, 464–469 (2012).

384 *BBmerge* – Bushnell, B., Rood, J. & Singer, E. BBMerge - Accurate paired shotgun read merging via overlap. *PLoS One* 12, e0185056
385 (2017).

386 *BLAST* – Altschul, S. F., Gish, W., Miller, W., Myers, E. W. & Lipman, D. J. Basic local alignment search tool. *J. Mol. Biol.* 215, 403–410
387 (1990).

388 *BWA-MEM* – Li, H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. *ArXiv E-Prints* (2013).

389 *CLC Main Workbench 8* – Qiagen. CLC Main Workbench version 8. Available at: <https://www.qiagenbioinformatics.com/>.

390 *cn.mops* – Klambauer, G. et al. cn.MOPS: mixture of Poissons for discovering copy number variations in next-generation sequencing
391 data with a low false discovery rate. *Nucleic Acids Res.* 40, e69 (2012).

392 *GapFiller* – Nadalin, F., Vezzi, F. & Policriti, A. GapFiller: a de novo assembly approach to fill the gap within paired reads. *BMC*
393 *Bioinformatics* 13 Suppl 14, S8 (2012).

394 *GATK* – McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing
395 data. *Genome Res* 20, 1297–303 (2010).

396 *GeneMark.hmm* – Besemer, J. GeneMarkS: a self-training method for prediction of gene starts in microbial genomes. Implications
397 for finding sequence motifs in regulatory regions. *Nucleic Acids Res.* 29, 2607–2618 (2001).

398 *GMAP* – Wu, T. D. & Nacu, S. Fast and SNP-tolerant detection of complex variants and splicing in short reads. *Bioinformatics* 26,
399 873–81 (2010).

400 *HINGE* – Kamath, G. M., Shomorony, I., Xia, F., Courtade, T. A. & Tse, D. N. HINGE: long-read assembly achieves optimal repeat
401 resolution. *Genome Res* 27, 747–756 (2017).

402 *i-ADHoRe 3.0* – Proost, S. et al. i-ADHoRe 3.0—fast and sensitive detection of genomic homology in extremely large data sets.
403 *Nucleic Acids Res.* 40, e11 (2012).

404 *Infernal* – Nawrocki, E. P. & Eddy, S. R. Infernal 1.1: 100-fold faster RNA homology searches. *Bioinformatics* 29, 2933–2935 (2013).

405 *Lordec* – Salmela, L. & Rivals, E. LoRDEC: accurate and efficient long read error correction. *Bioinformatics* 30, 3506–14 (2014).

406 *Pilon* – Walker, B. J. et al. Pilon: an integrated tool for comprehensive microbial variant detection and genome assembly
407 improvement. *PLoS One* 9, e112963 (2014).

408 *SnpEff and SnpSift* – Cingolani, P. et al. A program for annotating and predicting the effects of single nucleotide polymorphisms,
409 *SnpEff*. *Fly (Austin)* 6, 80–92 (2012).

410 *SPAdes* – Bankevich, A. et al. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. *J Comput*
411 *Biol* 19, 455–77 (2012).

412 *SSPACE-LongRead v3.0* – Boetzer, M. & Pirovano, W. SSPACE-LongRead: scaffolding bacterial draft genomes using long read
413 sequence information. *BMC Bioinformatics* 15, 211 (2014).

414 *TribeMCL* – van Dongen, S. & Abreu-Goodger, C. Using MCL to extract clusters from networks. *Methods Mol Biol* 804, 281–95
415 (2012).

416 *Trimmomatic* – Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics*
417 30, 2114–20 (2014).

418 *tRNAscan-SE* – Lowe, T. M. & Eddy, S. R. tRNAscan-SE: a program for improved detection of transfer RNA genes in genomic
419 sequence. *Nucleic Acids Res* 25, 955–64 (1997).

420 *UniProt* – The UniProt, C. UniProt: the universal protein knowledgebase. *Nucleic Acids Res* 45, D158–D169 (2017).

421

422

423 **SUPPLEMENTARY FIGURES**

424 **Supplementary Figure 1. DU1 duplication detection in BCG strains.** Tiling array data **(a)** from Leung *et al.* 2008¹³ and
425 Illumina sequencing data **(b)** for BCG Danish 1331 (this study) as well as published genome data from Pan *et al.* 2011⁷,
426 Abdallah *et al.* 2015⁸ and Festjens *et al.* 2018¹⁴ were reanalyzed for the presence of a DU1 in the region of the *oriC*.
427 These references were chosen as they contain BCG Danish genome sequencing data. The graphs in **(a)** depict the ratio
428 of the reference (*M. tb* H37Rv) probe intensity (Cy5) divided by the test (BCG strain) probe intensity as originally
429 presented in Leung *et al.* 2008¹³. The graphs in **(b)** depict the ratio of mean whole genome read coverage divided by
430 the mean read coverage in 500 bp window size. Detection of a DU1-like duplication in BCG Pasteur 1173P2¹³,
431 Birkhaug^{8,13}, Danish 1331 07/270 (this study) and BCG China^{7,13}, indicated in grey. No detection of DU1-duplication for
432 other BCG Pasteur^{8,14}, Danish^{7,8} and China⁸ strains.


433 **Supplementary Figure 2. Analysis of the SenX3-RegX3 region in BCG strains.** PCR was performed on gDNA of BCG
434 Danish 1331, Pasteur 1173 and 1721 using primer pair 9. This primer set was originally designed by Bedwell *et al.*
435 2001¹⁰ to identify BCG substrains by multiplex-PCR. Dependent on the number of repeats of 77 bp in the SenX3-RegX3
436 region a different amplicon is formed; a 353 bp amplicon for 3 repeats and a 276 bp amplicon for 2 repeats.

437 **Supplementary Figure 3. Genome analysis pipeline.**


438 **Supplementary Figure 4. Generation and characterization of BCG Danish 1331 *sapM* KO.** **a)** Plasmid map of suicide
439 vector pGOAL17SapM700. **b)** Hypothesis for the sequence of genomic rearrangements during production of BCG
440 Danish 1331 *sapM* KO from BCG Danish 1331 WT, which contains two *sapM* loci, due to the presence of the *sapM*
441 locus in the DU2 duplicated genomic region. **c)** Representation of the *sapM* WT and KO locus with indication of
442 theoretical PCR amplicons **(d)** and Southern blot fragments (PvuII digest and hybridization with Southern blot probe)
443 **(e)**. **d)** PCR analysis of the *sapM* locus. WT and *sapM* KO gDNA were amplified with primer pair 10. **e)** Southern blot for
444 the 5' part of *sapM* of *M. bovis* BCG WT and *sapM* KO after PvuII digest. **f)** Copy-number analysis of *sapM* and its
445 surrounding genes via qPCR on gDNA. Next to the truncation of *sapM*, the DU2 has been lost in the *sapM* KO, since all
446 duplicated genes in the DU2 are reduced to one copy in the *sapM* KO. The represented data are averages (\pm SD) of
447 four technical replicates. **g)** RT-PCR analysis of the *sapM* locus. RNA was prepared of cultures of biological triplicates of
448 the *sapM* KO and parental strain. RT-PCR on the cDNA was performed using primer sets directed against *sapM* and the
449 directly up- and downstream genes (*upp* and BCG_3376). The data presented here are averages (\pm SEM) of three
450 biological replicates. (*: $p < 0.05$). **h-i)** Analysis of SapM protein quantity and enzymatic activity. Strains were
451 subcultured from a mid-log culture to an OD₆₀₀ of 0.1, from which medium samples were collected for 8 days. ELISA
452 using an anti-SapM polyclonal antibody **(h)** and *in vitro* phosphatase assay using pNPP as a substrate to check
453 phosphatase activity **(i)**. The represented data are averages (\pm SD) of three biological replicates.

454 **Supplementary Figure 1**

455




456 **Supplementary Figure 2**



457


458 **Supplementary Figure 3**



459

460

461 **Supplementary Figure 4**



462

463

464 **SUPPLEMENTARY TABLES**

465 **Supplementary Table 1: Summary table of SNPs detected in *M. bovis* Danish 1331 WT and *sapM* KO compared to the Pasteur**
 466 **reference 1173P2 (NC_008679.1).**

Variants	Type	WT	KO	non-shared
SNP's	intergenic_region	9	9	0
	missense_variant	23	24	1
	stop_gained	1	1	0
	synonymous_variant	9	9	0
	total	42	43	1
genes affected by SNP's	missense_variants	18	19	1
	stop_gained	1	1	0
	total	19	20	1

467

468 **Supplementary Table 2. PCR primer pairs for confirmation of the genome assembly (pair 1-8), analysis of the SenX3-RegX3 region**
 469 **(pair 9) and validation of the KO engineering (pair 10)**

Primer set	Fw primer (5' -> 3')	Rv primer (5' -> 3')	Amplicon (bp)
Pair 1	GTTGTTTACCGTCCTCGG	GCCAGTCAATCGTCATC	804
Pair 2	GTCCAGCAGAAATGGCAG	GGTGACGCAGGTCTACAT	502
Pair 3	CATCAAACCTCGTCGCACA	GTTGGGGCGGTTTCATATC	675
Pair 4	CGAATCGCAGTTACCCCTG	ACGGATGATCTCTGCCAT	939
Pair 5	TTGCCAGGTGAAGGTAGT	CGTGGCTATCACTCCTCT	928
Pair 6	TAACTCCAGAACGGGACC	ATCGACTATCCGCCACTT	707
Pair 7	TAACAAGTCGGCTCCCTT	ATGGGATTGCCGTTGAAG	1130
Pair 8	ACCGCACAAAGTTAAGAG	TCTCCATACCGATAGCTG	987
Pair 9	GCGCGAGAGCCGAAGTGC	GCGCAGCAGAAACGTCAGC	353 (3 repeats), 276 (2 repeats)
Pair 10	AGAGACGCTCTCGAAGCCATACAGG	CCAGGGTATACCGTGCCTGG	1033 WT, 425 KO

470

471 **Supplementary Table 3. PCR primer pairs for confirmation of the SNP variants**

SNP Nb (Suppl. Table 2)	Position	Fw PCR primer (5' -> 3')	Rv PCR primer (5' -> 3')	Nested Sanger sequencing primer(s) (5' -> 3')
1	68923	ACTGGGCTGCAGTTGGATGAAC	ACCTGCCGAAGTCTCACAGAC	CACTGATCTTCCACTGACGTCTCATC
2	118865	GCTATGGACGCCATGGACTACGAC	CGAGGACAGCAACTCACCGAC	GATTGTGAATTCGCGTCCGACAC
5	623418	AGGACAGCAGCAGTCGACGTC	CATTTGGATCGGACAGCAACGAC	ACTGCAAGTTGCTGCACGAGC
8	759614	GATCAGGGACTGCGGATTGC	TATGGACGACGGCAAGGTCAAC	GACGCGAGATCACCGAACGAC
9	1324458	CTATGTCAATCCGACGTCGTACGC	CATGATCACAGCAAGCTGCC	ATGTGGTCCAGCGATGAAGTTGC
12	1661300	CTATCTGGCGGTGGTGTCTGC	AGTCGGTGGCAAAGGCAATAGC	GTAGTCAGATGGTTGGATCGCCAC
13	1661303			
14	1661304			
15	1661306			
16	1661307			
17	1661309			
18	1661323			
19	1906675	ATCCGTGTCGCACAATCCACAC	CTGCGAACCATGCAGTGAC	ATCGTCTGCCAATTGTCAGC
20	1937867	GATCAGCTCCGCTATTGCGCTC	GTTAACGCTGAATGCTCTGCAGTTC	GACCGAACCGTTATGCGTGACC
21	2002385	ATGTCCTGCTGCAGGTTGTGC	GCTGCTCAACTCGATCAACGC	CTTACCACCACCGAAGACAGTGC
25	2520484	AGACGCTGCCAGTTACGTGGTC	GAAGACGAGTTCGTGTGGTGTATGC	CAGTGCTCATCGACAATCGCAC
26	2619880	GCTCAGACGCCGTCTCATGAC	AGACGCTGCTAGATGACGGTC	CTGAAAGCTTCTTGCCTTCCAGC
27	2734209	CCACACCATTGACATGGATCGTC	GATCAAGGCCACCAGATAGGTGC	CCATGCCTTCCGCGATTGTC
29	2766103	ACAGGAAGCGATCCGGATTCTC	CAACGGCGGCATTGGTATCAC	CAAGCCACCATTACCAGCGTC
30	2860207	GTTGGCAGCTTATCGCCACC	ATGGACTCGATCCGTGAGGTGATC	GTTCAAGTCTGATGCAGTTCGATC
31	2976282	CTCTCGAAGCCGGAGTGAC	GAGCTCCTCATCGGTGGCTTC	GACTGATCTCGCTACTGATCGTGGC
34	3315469	CTGAATGATCGACAGGTCTGCGTC	AGATGACCAACCAGGAGCTGGC	GTGACACCGAGTCTCGTCTGTC
35	3443321	CTGAGCCTGCCCTAAGCCAGC	GACGGTATGGTATCCGTTTGTATC	CTATCAACGACGCCAGCGACAC
38	3716536	GAAGTCGATGACTTCGGGAGTGC	GGACTCCCATGTCCAACGCAC	CAGCACCGACGTCATCAGGC
39	3907860	GATCGGTGGCCAGGGTACC	GTGATGGTGGTGCCTGTGC	GTGATGGTGGTGCCTGTGC,
40	3908180			ACAACACCCTCAACCCCGACAC
43	4359392	GTTGACCATCGATGACCGCAC	ATCAACCGCACAAAGCAGTGGC	ATCAACCGCACAAAGCAGTGGC,
				CTACTCTGGCCACCGAGCAC

472 **Supplementary Table 4. qPCR primer pairs for copy number profiling**

Genes		Fw primer (5' -> 3')	Rv primer (5' -> 3')	
ref genes	16S rRNA	ATGACGGCCTTCGGTTGTAA	CGGCTGCTGGCACGTAGTTG	
	<i>nuoG</i>	CTGCTGCTGATCAACCATCC	CCGTTAGACATTGCCTGGTT	
	<i>mptpB</i>	CCGCGTCATTATCGACTGG	CGCATTCAAGAGGCTGCTAA	
DU1	<i>esxF</i>	CAGTTGAACCGGAGATG	CTGGGCATTGTTAGGTTGC	
	BCG_3957c	GATCGTCACCGATATCTTCG	TCCAAACCAGGTGCAATG	
	<i>sigMa</i>	GCCAGGGTGAAGTGCTATG	CGGAACAACGATCGAAGG	
	<i>trxB2</i>	TACCGACGCATTGATAGGAG	CAAAAGTCAACCAGCACAGG	
	<i>parB</i>	CCATCAGTGGTCATCAAACC	ATGTTGCTGAGCGTCTATCG	
	<i>rpmH</i>	GTTGCAATCAAGCACTGAGC	GTTACCGGTTCCGCTTAC	
	<i>dnaN</i>	TGGCTGTTTCGAGAACTGAAG	ACGACAAACGAAACGTCAGAG	
	<i>recF</i>	CTTCGAGCTGTGTTGTTTGC	TCGCCAGATCATCCAGATAG	
	<i>gyrA</i>	GCTGATCCGCTATTACGTTG	ATCAGTGCAATGACCTCGTC	
	BCG_0012	GTTGTGCATCAGCAAGACATC	CGACACAACGAGCTATCGAC	
	<i>pknA</i>	CATTGCGCTATCTCGTATCG	CGACTCAATTGGACGGAAC	
	BCG_0051	ATTGGCGATGCTGTAGTCAC	CGAACTCGACATTCTCCATC	
	DU2	<i>whiB7</i>	TCACACACAGTGCTTTGGCTAC	AGACCCCCAGACAAAGATTG
		BCG_3268c	CTTTGAGAACGATGCTGTCC	TTGCTATCTCTCCACGAAGG
BCG_3301		AAACTGGCAGAAGCTGTG	CCAGTGCCAATTCCAACTC	
<i>atsB</i>		AACACCGGTTTCGTTCAATG	CCGTATTGTTTCGATCAGCTC	
<i>upp</i>		CACGCTGCTGTTGATCTATG	GGGCAGCGAGTCCAGATA	
<i>sapM</i> 5'		AGGGTATACCGTGCCTTGG	GTTCTCCTCCACCACGATG	
<i>sapM</i> 3'		TGCGGCCCGAACTTACAACGAGA	CAAGCGGATGGGTACGAGGTCAGC	
BCG_3376		AAGTTCTTCAACGGCAATCC	GTGCTGATGATCTCGTCGAT	
<i>cdd</i>		GGAGCCTATGTGCCGATTC	CGCACAAAGTCAAGCCATAC	

473